Study: 85% of BMP Procedures Between 2002 and 2007 Used for Off-Label Applications

Spine

At least 85 percent of principle procedures using Bone Morphogenetic Proteins (BMP) from 2002-2007 were for off-label applications, according to an article published in Spine.

The FDA currently only approves BMP usage for anterior lumbar interbody fusion, but the use of BMP on additional spinal fusion procedures is on the rise, according to the article.

Researchers examined the prevalence of BMP usage in the United States using the Nationwide Inpatient Sample between Oct. 1, 2002 and Dec. 31, 2007. The principal procedure associated with BMP use was determined, as well as calculated the prevalence of use for various population subgroups.

The researchers found the number of procedures involving BMP increased by 4.3-fold during the study period. Spine fusion accounted for 92.8 percent of principle procedures with BMP, predominantly used in primary posterior lumbar interbody fusion or transformational interbody fusion.

Read the abstract for "Off-Label Use of Bone Morphogenetic Proteins in the United States Using Administrative Data."

Read other coverage about spine surgery studies:

- Minimally Invasive Decompression Revision Rates Higher for Scoliosis Patients


- Study: Vertebroplasty Effective in Some Compression Fracture Patients

- Researchers Develop Score Chart Predicting Outcomes for Nonspecific Neck Pain

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.